Cargando…

Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma

BACKGROUND: Patients with high-risk, newly diagnosed multiple myeloma (HR-NDMM) who are ineligible for autologous stem cell transplant (ASCT) have limited first-line treatment options. Recent meta-analyses evaluating the impact of incorporating daratumumab in the backbone regimen on progression-free...

Descripción completa

Detalles Bibliográficos
Autores principales: Jakubowiak, Andrzej J, Kumar, Shaji, Medhekar, Rohan, Pei, Huiling, Lefebvre, Patrick, Kaila, Shuchita, He, Jianming, Lafeuille, Marie-Hélène, Cortoos, Annelore, Londhe, Anil, Mavros, Panagiotis, Lin, Thomas S, Usmani, Saad Z
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256027/
https://www.ncbi.nlm.nih.gov/pubmed/35462406
http://dx.doi.org/10.1093/oncolo/oyac067